From Financial Modeling Prep: 2024-12-24 16:00:02

Ardelyx, Inc. (NASDAQ:ARDX) has a negative Return on Invested Capital (ROIC) of -24.68%, highlighting inefficiencies in capital utilization. Peers like Kala Pharmaceuticals (KALA) and Aldeyra Therapeutics (ALDX) also exhibit negative ROICs, indicating widespread challenges in the sector. In contrast, Akebia Therapeutics (AKBA) stands out with a remarkable ROIC of 346.81%.

Ardelyx is a biopharmaceutical company focusing on gastrointestinal and cardiorenal diseases. Its ROIC of -24.68% is lower than its WACC of 9.12%, signaling inefficiencies in capital use. Akebia Therapeutics, on the other hand, boasts an impressive ROIC of 346.81% against a WACC of 7.35%, showcasing efficient capital utilization.

Kala Pharmaceuticals (KALA) and Aldeyra Therapeutics (ALDX) have negative ROICs of -82.67% and -46.04%, respectively, indicating significant inefficiencies in capital utilization. CytomX Therapeutics (CTMX) and Cidara Therapeutics (CDTX) also face challenges with negative ROICs. Despite this, Akebia Therapeutics remains the most efficient in capital utilization.



Read more at Financial Modeling Prep:: Ardelyx, Inc. (NASDAQ:ARDX) Capital Efficiency Ana…